Fate therapeutics announces new preclinical data for ft596 off-the-shelf, ipsc-derived car nk cell cancer immunotherapy

Fate therapeutics announces new preclinical data for ft596 off-the-shelf, ipsc-derived car nk cell cancer immunotherapy.fate therapeutics-combination of ft596 with rituximab shows durable tumor clearance in vivo in preclinical lymphoma model.fate therapeutics-co plans to initiate enrollment of first-in-human clinical trial of ft596 in early 2020.
FATE Ratings Summary
FATE Quant Ranking